PS
ONCY

Principal Securities’s Oncolytics Biotech ONCY Stock Holding History

Principal Securities’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,000
Closed -$2.61K – 3606
2024
Q3 		$2.61K Buy
+3,000
New +$2.95K ﹤0.01% 2874

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Principal Securities's ONCY Position: Q4 2024 in Review

Principal Securities sold out of Oncolytics Biotech (ONCY) in Q4 2024, closing a stake of 3,000 shares — an estimated $2.61K sold.

Principal Securities first reported a position in ONCY in Q3 2024 and held it in 1 quarter. The position peaked at $2.61K in Q3 2024. 46 funds tracked by Wall St. Rank hold ONCY as of Q4 2024.

  • Principal Securities reported no remaining Oncolytics Biotech position as of Q4 2024 after selling out during the quarter.
  • Principal Securities sold 3,000 Oncolytics Biotech shares in Q4 2024, an estimated $2.61K.
  • Principal Securities first reported a position in Oncolytics Biotech in Q3 2024 and held it in 1 quarter.
  • Principal Securities's Oncolytics Biotech position peaked at $2.61K in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2024.

Based on Principal Securities's 13F filing for Q4 2024, filed 30 Jan 2025.